Another fun one is a piece which quotes someone making the classic misinterpretation and then someone else immediately correcting them. From "Drug Trials: Often Long On Hype, Short on Gains; The delusion of ‘significance’ in drug trials":
Part of the problem, said Alex Adjei, PhD, the senior vice president of clinical research and professor and chair of the Department of Medicine at Roswell Park Cancer Institute in Buffalo, N.Y., is that oncology has lost focus on what exactly a P value means. “A P value of less than 0.05 simply means that there is less than a 5% chance that the difference between two medications—whatever it is—is not real, that it’s just chance. If there’s a four-week overall survival difference between two drugs and my P value is less than 0.05, it’s statistically significant, but that just means that the number in the study is large enough to tell me that the difference I’m seeing is not by chance. It doesn’t tell me if those additional four weeks are clinically significant.”
“P values are even more complicated than that,” said Dr. Berry. “No one understands P values, because they are fundamentally non-understandable.” (He elaborates on this problem in “Multiplicities in Cancer Research: Unique and Necessary Evils,” a commentary in August in the Journal of the National Cancer Institute [2012;104:1125-1133].)
Also fun, "You do not understand what a p-value is (p < 0.001)":
Here's what the p-value is not: "The probability that the null-hypothesis was true." I didn't choose this definition out of thin air to beat up on, it was the correct answer on a test I took asking, "Which of these is the definition of a p-value?"
Another entry from the 'no one understands p-values' files; "Policy: Twenty tips for interpreting scientific claims", Sutherland et al 2013, Nature - there's a lot to like in this article, and it's definitely worth remembering most of the 20 tips, except for the one on p-values:
...Significance is significant. Expressed as P, statistical significance is a measure of how likely a result is to occur by chance. Thus P = 0.01 means there is a 1-in-100 probability that what looks like an effect of the treatment could have occurred randomly, and in truth
Frequentist statistics is a wide field, but in practice by innumerable psychologists, biologists, economists etc, frequentism tends to be a particular style called “Null Hypothesis Significance Testing” (NHST) descended from R.A. Fisher (as opposed to eg. Neyman-Pearson) which is focused on
NHST became nearly universal between the 1940s & 1960s (see Gigerenzer 2004, pg18), and has been heavily criticized for as long. Frequentists criticize it for:
What’s wrong with NHST? Well, among other things, it does not tell us what we want to know, and we so much want to know what we want to know that, out of desperation, we nevertheless believe that it does! What we want to know is, “Given these data, what is the probability that H0 is true?” But as most of us know, what it tells us is “Given that H0 is true, what is the probability of these (or more extreme) data?” These are not the same…
Similarly, the cargo-culting encourages misuse of two-tailed tests, avoidance of multiple correction, data dredging, and in general, “p-value hacking”.
(An example from my personal experience of the cost of ignoring effect size and confidence intervals: p-values cannot (easily) be used to compile a meta-analysis (pooling of multiple studies); hence, studies often do not include the necessary information about means, standard deviations, or effect sizes & confidence intervals which one could use directly. So authors must be contacted, and they may refuse to provide the information or they may no longer be available; both have happened to me in trying to do my dual n-back & iodine meta-analyses.)
Critics’ explanations for why a flawed paradigm is still so popular focus on the ease of use and its weakness; from Gigerenzer 2004:
Shifts away from NHST have happened in some fields. Medical testing seems to have made such a shift (I suspect due to the rise of meta-analysis):
0.1 Further reading
More on these topics:
The perils of NHST, and the merits of Bayesian data analysis, have been expounded with increasing force in recent years (e.g., W. Edwards, Lindman, & Savage, 1963; Kruschke, 2010b, 2010a, 2011c; Lee & Wagenmakers, 2005; Wagenmakers, 2007).
Although the primary emphasis in psychology is to publish results on the basis of NHST (Cumming et al., 2007; Rosenthal, 1979), the use of NHST has long been controversial. Numerous researchers have argued that reliance on NHST is counterproductive, due in large part because p values fail to convey such useful information as effect size and likelihood of replication (Clark, 1963; Cumming, 2008; Killeen, 2005; Kline, 2009 [Becoming a behavioral science researcher: A guide to producing research that matters]; Rozeboom, 1960). Indeed, some have argued that NHST has severely impeded scientific progress (Cohen, 1994; Schmidt, 1996) and has confused interpretations of clinical trials (Cicchetti et al., 2011; Ocana & Tannock, 2011). Some researchers have stated that it is important to use multiple, converging tests alongside NHST, including effect sizes and confidence intervals (Hubbard & Lindsay, 2008; Schmidt, 1996). Others still have called for NHST to be completely abandoned (e.g., Carver, 1978).
[http://www.gwern.net/DNB%20FAQ#flaws-in-mainstream-science-and-psychology](http://www.gwern.net/DNB%20FAQ#flaws-in-mainstream-science-and-psychology)[https://www.reddit.com/r/DecisionTheory/](https://www.reddit.com/r/DecisionTheory/)